The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Differential activity of afatinib (AFAT), cetuximab (CET), and erlotinib (E) in a patient-derived xenograft (PDX) model of acquired E resistance.
Philip C. Mack
Consultant or Advisory Role - Boehringer Ingelheim; MolecularMD
Honoraria - Boehringer Ingelheim
Neal Goodwin
No relevant relationships to disclose
William S. Holland
No relevant relationships to disclose
Karen Kelly
No relevant relationships to disclose
Primo Lara
Consultant or Advisory Role - Agennix; Genentech; Immunogen; Medivation; Pfizer; Teva
Honoraria - Elsevier
Research Funding - Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Millennium; NCI
David R. Gandara
No relevant relationships to disclose